Investment Thesis
We believe that potential common stock investors should avoid Rosehill Resources (ROSE) as it pursues a very aggressive growth strategy until it becomes clearer whether Rosehill will ever be able to generate positive free cash flow.
Rosehill completes previously announced Southern Delaware basin transaction
After the close of the market on December 14, 2017, Rosehill Resources issued a press release announcing that it had completed a $78 million South Delaware Basin acreage acquisition it previously announced. The 4,565 net acre acquisition brings Rosehill’s total to 9,200 net acres.
Rosehill may acquire up to an additional 4,500 net acres under the same terms, subject to certain conditions.
The transaction establishes a second core operation area in the Delaware Basin that provides it with enough size to operate efficiently. Management provided a slide presentation with more details including the location of the additional acreage.
Rosehill raised $250M of expensive financing to fund the transaction in combination of debt and preferred stock
As part of the announcement of the acquisition closing, Rosehill management announced $250 million in financing in a combination of $100 in senior secured second lien debt maturing in 2023 and $150 million in redeemable Series B preferred stock.
stock market patterns: Oshkosh Corporation(OSK)
Advisors’ Opinion:
- [By WWW.THESTREET.COM]
Oshkosh (OSK) was downgraded to neutral from buy at Bank of America/Merrill Lynch. $62 price target. The valuation is less attractive, as the stock is trading at 21x expected 2017 earnings, analysts said.
- [By Shanthi Rexaline]
The six companies that met the criterion are:
Oshkosh Corp (NYSE: OSK). Phillips 66 (NYSE: PSX). SpartanNash Co (NASDAQ: SPTN). Suncor Energy Inc. (USA) (NYSE: SU). Washington Federal Inc. (NASDAQ: WAFD). Barnes & Noble, Inc. (NYSE: BKS).
OshkoshOshkosh is a manufacturer of specialty vehicles and vehicle bodies and is based in Wisconsin. The company operates under four business segments, namely access equipment, defense, fire and emergency, and commercial.
- [By Rich Smith]
I first named Oshkosh my top stock pick back in September, when the stock cost $42 and change. Since then, the stock has gone down, and sells for $3 less. So am I supposed to dislike Oshkosh stock now?
No. To the contrary, I like it even more. (About $3 more, in fact).
You see, even in the process of picking Oshkosh back then, I warned investors: "I don’t know whether Oshkosh will be the best-performing stock in the world in the month of September, but I’ve got a strong hunch about the next six months." And that hunch remains — because the facts have not changed.
This past summer, Oshkosh was named the winner of the Pentagon’s contract to build a next-gen "Humvee" — an armored Joint Light Tactical Vehicle that will serve the U.S. military for decades to come. Oshkosh won an initial award to produce 17,000 vehicles for $6.7 billion. Ultimately, though, this is a contract that could swell to $30 billion or more for production, maintenance, and upgrade of approximately 55,000 JLTVs across all military branches.
So why hasn’t Oshkosh stock moved in response to the contract? Mainly because rival bidderLockheed Martin threw a monkey wrench into the contracts process, first protesting the JLTV award to Oshkosh, and then, when that protest was rejected, filing suit in court to try to win the contract away from its rival.
Personally, I think Lockheed Martin will lose that suit as well. After all, Lockheed’s forte is in fighter jets, while Oshkosh is the military’s premier supplier of trucks like JLTV, as well as the Army’s M-ATV vehicle (a small, all-terrain MRAP). Perhaps recognizing this, AM General, the other company that bid against Oshkosh on JLTV and lost, declined to protest the award. Lockheed took the other road, but I expect it will be a dead end for Lockheed as well.
stock market patterns: Sunoco LP(SUN)
Advisors’ Opinion:
- [By Lisa Levin]
Here is the list of stocks going ex-dividend on August 3, 2016.
J B Hunt Transport Services Inc (NASDAQ: JBHT) – $0.2200 dividend, 1.0791 percent yield
Johnson Controls Inc (NYSE: JCI) – $0.2900 dividend, 2.6250 percent yield
FirstEnergy Corp. (NYSE: FE) – $0.3600 dividend, 3.9680 percent yield
Sunoco LP (NYSE: SUN) – $0.8255 dividend, 10.7347 percent yield
Wells Fargo & Co (NYSE: WFC) – $0.3800 dividend, 3.1588 percent yield
BP plc (ADR) (NYSE: BP) – $0.6000 dividend, 6.8768 percent yield
American Airlines Group Inc (NASDAQ: AAL) – $0.1000 dividend, 1.1442 percent yield
Heidrick & Struggles International, Inc. (NASDAQ: HSII) – $0.1300 dividend, 2.9834 percent yield
Alcoa Inc (NYSE: AA) – $0.0300 dividend, 1.1321 percent yield
Sensient Technologies Corporation (NYSE: SXT) – $0.2700 dividend, 1.5341 percent yield
Posted-In: Ex-DividendNews Dividends Markets Trading Ideas
- [By Douglas A. McIntyre]
Exxon Mobil Corp. (NYSE: XOM) is the second largest company in America and the world’s largest oil company. Chevron Corp. (NYSE: CVX) is the third largest company in the United States. Valero Corp. (NYSE: VLO) is among the world’s largest refiners. Sunoco L.P. (NYSE: SUN) is one of North America’s largest owners of stations and convenience stores. BP PLC (NYSE: BP) is among the world’s oil behemoths. Shell is the U.S. branch of oil giant Royal Dutch Shell PLC (NYSE: RDS-A).
- [By Lisa Levin]
Friday afternoon, the non-cyclical consumer goods & services sector proved to be a source of strength for the market. Leading the sector was strength from Ballard Power Systems Inc. (USA) (NASDAQ: BLDP) and Sunoco LP (NYSE: SUN).
- [By Lisa Levin]
Thursday afternoon, the energy sector proved to be a source of strength for the market. Leading the sector was strength from Ballard Power Systems Inc. (USA) (NASDAQ: BLDP) and Sunoco LP (NYSE: SUN).
stock market patterns: Motorola Solutions, Inc.(MSI)
Advisors’ Opinion:
- [By Peter Graham]
A long term performance chart shows large caps Cisco Systems and Motorola Solutions Inc (NYSE: MSI) giving roughly the same positive albeit sometimes bumpy performance whileQualcomm, Inc (NASDAQ: QCOM) has fallen in and out of negative territory:
- [By Peter Graham]
A long term performance chart shows Qualcomm breaking even whilepotential peers Cisco Systems, Inc (NASDAQ: CSCO) and Motorola Solutions Inc (NYSE: MSI) have performed better albeit they have seen their share of volatility:
- [By Peter Graham]
A long term performance chart shows large caps Cisco Systems and Motorola Solutions Inc (NYSE: MSI) giving roughly the same performance whileQualcomm, Inc (NASDAQ: QCOM) began going in the other directionaround 2015:
- [By Peter Graham]
A long term performance chart shows large caps Cisco Systems and Motorola Solutions Inc (NYSE: MSI) giving roughly the same positive performance whileQualcomm, Inc (NASDAQ: QCOM) began going in the other directionaround 2014/2015:
stock market patterns: EP Energy Corporation(EPE)
Advisors’ Opinion:
- [By Paul Ausick]
EP Energy Corp. (NYSE: EPE) posted a new 52-week low of $1.85 Tuesday, down nearly 22% after closing at $2.37 on Monday. The 52-week high is $7.49. Volume was about 3.2 million, around 5 times the daily average of around 600,000. The oil and gas exploration and production firm has launched an exchange program extending the maturity date to 2024 on $1.2 billion in 9.375% notes due in 2020.
- [By Andrew Efimoff]
WTI crude oil plunged 3.11 percent on Friday to $48.99 a barrel. Below are the biggest energy losers for the day:
California Resources Corporation (NYSE: CRC): -19.22%
Dynamic Materials (NASDAQ: BOOM): -12.39%
Clayton Williams Energy (NYSE: CWEI): -11.45%
Dynergy (NYSE: DYN): -11.91%
EP Energy Corporation (NYSE: EPE): -11.20%
Mexco Energy (NYSE: MXC) -10.90%
Whiting Petroleum (NYSE: WLL) -10.79%
Southwestern Energy Company (NYSE: SWN) -10.79%
SM Energy Company (NYSE: SM) -10.38%
Real Goods Solar (NASDAQ: RGSE) -10.34%Posted-In: Commodities After-Hours Center Markets Movers
stock market patterns: Celgene Corporation(CELG)
Advisors’ Opinion:
- [By Chris Lange]
Celgene Corp. (NASDAQ: CELG) short interest for this settlement date increased to 9.97 million shares from the previous 9.26 million. Shares closed most recently at $121.06, in a 52-week range of $93.05 to $127.00.
- [By Peter Graham]
A long term performance shows shares of small cap cancer stocks Juno Therapeutics and Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) underperforming whileKite Pharma Inc (NASDAQ: KITE)andlarge cap Celgene Corporation (NASDAQ: CELG) have performed better:
- [By WWW.THESTREET.COM]
Originally published Nov. 17 at 3:41 p.m. EDT
The consideration of the contrary has been a theme all week. And here in ” Don’t Run With the Crowd: Embrace the Contrary.” Miami madness (of a real estate kind) Mark Grant is scared by our currency’s strength. Danielle on scenarios. Boockvar to subscriber Bad Golfer! JC Penney ( JCP) short puts–a 100% win. (Shorting options frequently ends differently!) Just say no to closed-end muni-bond funds. DRYS is all wet. Could iPhone manufacturing be coming back home? On inflation breakevens–a picture that speaks volumes. The market moved higher from the “get go”–in large measure it seems to be a response to the better economic data this morning. At 3 p.m. stocks were near the day’s highs. I shorted The Cisco Kid last night. Sticking with this short rental. I added to my ProShares UltraShort S&P500 ETF ( SDS) long (growing ever larger). My net short exposure–is now between small and medium-sized at the close. The U.S. dollar, as discussed above, continued to rip higher against the euro. I am concerned. Mark Grant is concerned. The market is not concerned. The price of crude oil (down $0.20) settled lower after yesterday’s robust gains. Gold fell $9 as it continues to break down–closing in on $1,200. Ag commodities: wheat up $0.07, corn up $0.04, soybeans up $0.05 and oats up $0.02. Lumber up $7 following the big housing number this morning. Bonds schmeissed … iShares Barclays 2
- [By JACK HOUGH]
Celgene’s main risk is a little like AMC’s zombies. It will generate more than 60% of its revenue this year from a single medicine called Revlimid, used primarily to treat a type of cancer called multiple myeloma. But Revlimid is gaining regulatory approval for an expanding number of uses. It has plenty of growth potential overseas, and shows promise in combination therapies. And it has more than a decade of remaining patent protection. Analysts predict double-digit yearly revenue growth for Revlimid through the end of the decade.
By then, Celgene is expected to have four drugs with yearly sales in the billions of dollars, versus just Revlimid today. And a robust pipeline of medicines in development provides ample opportunity for new successes. Management has set a goal of $21 billion in yearly revenue by 2020, up from a projected $9.2 billion this year. If it’s successful, two things are likely to happen. First, Revlimid’s contribution is likely to drop below half of revenue by then. Second, earnings per share could more than double, as Celgene’s growing size offers better leverage on its research and marketing expenses. Shares sell for 22 times this year’s earnings consensus—inexpensive considering the growth outlook.
- [By Ben Levisohn]
Three biotech stocks–Alexion Pharmaceuticals (ALXN), Amgen (AMGN), and Celgene (CELG)–reported earnings since yesterday’s close. But just one has seen its shares head higher after the announcement.
